TY - JOUR
T1 - D -Penicillamine modulates hydrogen sulfide (H2S) pathway through selective inhibition of cystathionine-γ-lyase
AU - Brancaleone, Vincenzo
AU - Esposito, Iolanda
AU - Gargiulo, Antonella
AU - Vellecco, Valentina
AU - Asimakopoulou, Antonia
AU - Citi, Valentina
AU - Calderone, Vincenzo
AU - Gobbetti, Thomas
AU - Perretti, Mauro
AU - Papapetropoulos, Andreas
AU - Bucci, Mariarosaria
AU - Cirino, Giuseppe
N1 - Publisher Copyright:
© 2016 The British Pharmacological Society.
PY - 2016/5/1
Y1 - 2016/5/1
N2 - Background and Purpose Hydrogen sulfide (H2S) is a gasotransmitter produced from l-cysteine through the enzymatic action of cystathionine-γ-lyase (CSE) and/or cystathionine-β-synthase. d-Penicillamine is the d isomer of a dimethylated cysteine and has been used for the treatment of rheumatoid arthritis. As d-penicillamine is structurally very similar to cysteine, we have investigated whether d-penicillamine, as a cysteine analogue, has an effect on the H2S pathway. Experimental Approach We tested the effect of d-penicillamine (0.01-1 mM) in mouse aortic rings mounted in isolated organ baths and determined whether it could affect H2S biosynthesis. In particular, we investigated any possible inhibitor or donor behaviour by using recombinant enzyme-based assays and an in vivo approach. Key Results d-Penicillamine, per se, showed little or no vasodilator effect, and it cannot be metabolized as a substrate in place of l-cysteine. However, d-penicillamine significantly reduced l-cysteine-induced vasodilatation in a concentration-dependent manner through inhibition of H2S biosynthesis, and this effect occurred at concentrations 10 times lower than those needed to induce the release of H2S. In particular, d-penicillamine selectively inhibited CSE in a pyridoxal-5′-phospate-dependent manner. Conclusions and Implications Taken together, our results suggest that d-penicillamine acts as a selective CSE inhibitor, leading to new perspectives in the design and use of specific pharmacological tools for H2S research. In addition, the inhibitory effect of d-penicillamine on CSE could account for its beneficial action in rheumatoid arthritis patients, where H2S has been shown to have a detrimental effect.
AB - Background and Purpose Hydrogen sulfide (H2S) is a gasotransmitter produced from l-cysteine through the enzymatic action of cystathionine-γ-lyase (CSE) and/or cystathionine-β-synthase. d-Penicillamine is the d isomer of a dimethylated cysteine and has been used for the treatment of rheumatoid arthritis. As d-penicillamine is structurally very similar to cysteine, we have investigated whether d-penicillamine, as a cysteine analogue, has an effect on the H2S pathway. Experimental Approach We tested the effect of d-penicillamine (0.01-1 mM) in mouse aortic rings mounted in isolated organ baths and determined whether it could affect H2S biosynthesis. In particular, we investigated any possible inhibitor or donor behaviour by using recombinant enzyme-based assays and an in vivo approach. Key Results d-Penicillamine, per se, showed little or no vasodilator effect, and it cannot be metabolized as a substrate in place of l-cysteine. However, d-penicillamine significantly reduced l-cysteine-induced vasodilatation in a concentration-dependent manner through inhibition of H2S biosynthesis, and this effect occurred at concentrations 10 times lower than those needed to induce the release of H2S. In particular, d-penicillamine selectively inhibited CSE in a pyridoxal-5′-phospate-dependent manner. Conclusions and Implications Taken together, our results suggest that d-penicillamine acts as a selective CSE inhibitor, leading to new perspectives in the design and use of specific pharmacological tools for H2S research. In addition, the inhibitory effect of d-penicillamine on CSE could account for its beneficial action in rheumatoid arthritis patients, where H2S has been shown to have a detrimental effect.
UR - http://www.scopus.com/inward/record.url?scp=84961839275&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84961839275&partnerID=8YFLogxK
U2 - 10.1111/bph.13459
DO - 10.1111/bph.13459
M3 - Article
C2 - 26890936
AN - SCOPUS:84961839275
SN - 0007-1188
VL - 173
SP - 1556
EP - 1565
JO - British Journal of Pharmacology
JF - British Journal of Pharmacology
IS - 9
ER -